Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunovirologic effects of maraviroc interruption in patients failing a maraviroc-containing regimen
2010-021651-79Phase 2Terminated
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aprepitant in human immunodeficiency virus infection (HIV), sponsored by Fondazione Centro San Raffaele. Primary endpoint: Proportion of patients with at least 0.5 log10 increase in HIV-1 RNA at week 12. Started Apr 2012; status: terminated.
02
Drugs
aprepitant
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2010-021651-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021651-79.